VIRADIA: a virtual reality app for neurological and cognitive testing
Official title: Validation Study of VIRADIA: A Virtual Reality Diagnostic Platform for the Assessment of Neurological and Cognitive Functions
Run by Gametherapy · NCT07268079 · Data updated 2026-11-12
This project tests whether the VIRADIA virtual reality app gives comparable results to standard paper or in-person neurological and cognitive tests for adults with and without neurological conditions.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Gametherapy Academic / other |
| Locations | 1 site (Nitra, Nitra Region) |
| Status | Recruiting |
| Started | December 1, 2025 |
| Main results expected | March 31, 2026 |
| Study ends | May 1, 2026 |
| Registry record updated | December 5, 2025 |
| Trial ID | NCT07268079 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–80 who can give informed consent, have adequate vision and hearing, and are either healthy volunteers or have a confirmed neurological diagnosis (for example Parkinson's disease or multiple sclerosis).
✕Probably not a fit
Patients with severe cognitive impairment (e.g., MMSE <24), major motor disabilities that prevent using a VR controller, uncorrected visual or vestibular conditions causing VR intolerance, acute psychiatric conditions, or current substance abuse are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The VIRADIA validation uses a within-subjects, paired design in which healthy volunteers and people with neurological diagnoses complete both standard (paper or face-to-face) and VR versions of nine common clinical tests. Test order is randomly assigned to control for order effects, and measures cover fine motor coordination (9-Hole Peg Test), gait and balance (6‑Meter Walk, TUG‑M, Functional Reach), processing speed and attention (SDMT), and visuospatial/executive function (Clock Drawing, Trail Making). Demographic and clinical data are recorded and participants complete a brief questionnaire on VR tolerability and subjective experience. Analyses focus on convergent validity (agreement between VR and standard scores) and discriminative validity (ability of VR measures to distinguish healthy controls from neurological patients).
Why it matters
Potential benefit: If successful, VIRADIA could provide a standardized, more accessible way to perform neurological and cognitive tests that supports clinic-based or remote monitoring and earlier detection of change.
How similar studies have gone: Previous VR adaptations of cognitive and motor assessments have shown promising correlations with traditional measures, but large-scale, cross-condition validation data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-80 years. * Ability to provide informed consent. * Adequate vision and hearing to complete testing. * For the neurological group: confirmed diagnosis of a neurological disorder (e.g., Parkinson's disease, multiple sclerosis, or similar). * For the control group: no history of neurological or psychiatric disease. Exclusion Criteria: * Severe cognitive impairment (MMSE \< 24 or equivalent clinical judgment). * Acute neurological or psychiatric condition interfering with testing. * Severe motor disability preventing task performance (e.g., inability to use VR controller). * Current substance abuse. * Uncorrected visual impairment or vestibular disorder leading to intolerance of VR.
Where it's running
-
INNER s.r.o., Fatranská 873/12, 94901 Nitra
Nitra, Nitra Region, Slovakia Recruiting
Study contacts
- Principal investigator: Ingrid Menkyova, MD, PhD.
- Study coordinator: Martin Polak, Dr.
- Email: martin@gametherapy.eu
- Phone: +421915546098
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment for neurologic disorders using stem cells
This study is testing whether using stem cells from patients' own bone marrow can help improve brain and nerve function in people with serious neurologic disorders that don't respond well to regular treatments.
-
Collecting data on neurodegenerative diseases progression markers
This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.
-
Cohort study on Alzheimer's risk in first-degree relatives
This study looks at how likely first-degree relatives of Alzheimer's patients are to develop the disease themselves and what factors might affect that risk.
-
Using a passive home sensor to find digital signs of brain energy changes from nicotinamide riboside
This project will try a contact-free home sensor to see if it can detect activity, sleep, and breathing changes related to nicotinamide riboside in people with mild cognitive impairment or mild Alzheimer's.
-
Registering medical data and care outcomes for ALS, SMA, and other motor disorders
This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.
-
Advanced 7T fMRI for brain function in epilepsy and brain injuries
This study tests ultra-high-field brain scans at 7T to see if they can better map brain function in adults with epilepsy or brain lesions and in healthy volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.